Developer docs
API playgroundTry for free, no card

Search company profiles

Foresite Labs

Full company profile

uuid0005oei

Namestring
Foresite Labs
Legal namestring
Foresite Labs, LLC
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Foresite Labs, LLC is a San Francisco–based AI and data science company incubation platform founded in 2019 by Jim Tananbaum and Vik Bajaj, operating as the operational arm of the broader Foresite organization alongside Foresite Capital (founded 2011, ~$3.5B AUM). The firm identifies scientific and technological opportunities—primarily at the intersection of AI, life sciences, and increasingly the physical economy—and recruits founders to co-build companies, supplying capital, scientific infrastructure, data resources, and operational support through incubation. Its platform integrates AI, data science, and advanced analytics to analyze large-scale clinical, genomic, and multi-omics datasets, with a standardized data ecosystem that compounds learnings across ventures.

Notable incubated companies include Prometheus (AI for the physical economy, co-incubated with Arch Ventures in 2024, $41B valuation by June 2026 with Jeff Bezos as co-CEO), Xaira Therapeutics (AI drug discovery, $1B Series A in April 2024), Alumis (TYK2 inhibitors for autoimmune disease, NASDAQ: ALMS, $345.1M IPO), and Candid Therapeutics (T-cell engagers for autoimmune disease, acquired by UCB in May 2026). Foresite Labs also operates a dedicated $173M fund (launched March 2022) to back portfolio companies, and maintains offices in San Francisco and Boston with a team of approximately 18 scientists, engineers, and operators.

The business model is venture-studio returns: equity creation and appreciation in incubated companies, realized through IPOs, acquisitions, and subsequent financings, supplemented by management fees on the dedicated fund. Foresite Labs does not sell products or services to external customers; rather, it distributes its capabilities through direct partnerships with founders it recruits and co-invests alongside financial partners such as Arch Ventures and Foresite Capital.

Short descriptiontext

Foresite Labs is an AI and data science company incubation platform founded in 2019 that co-builds transformative ventures in life sciences and the physical economy alongside founders, supplying capital, scientific infrastructure, and operational support through a dedicated $173M fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech incubation platform, AI drug discovery, venture studio services, company formation platform, data science incubation
Industry2 codes
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Management Consulting Services54161
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Biotech Incubation Platform
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Portfolio Company Success
TypeLicensing Royalties
Description

Foresite Labs generates returns through successful exits and appreciation of equity stakes in incubated companies. The firm provides incubation services, capital, and operational support to early-stage ventures, with returns realized through IPOs, acquisitions, or subsequent funding rounds.

foresitelabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Foresite Labs operates an AI- and data-science-driven company incubation platform that identifies scientific opportunities, recruits visionary entrepreneurs, and provides capital, scientific infrastructure, data capabilities, and operational support to co-found and scale transformational companies. Its portfolio spans AI-powered drug discovery (Xaira Therapeutics), autoimmune therapeutics (Alumis, Candid Therapeutics), and AI for the physical economy (Prometheus). The firm monetizes through equity appreciation and successful exits of incubated companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Prometheus reached $41 billion valuation within 2 years of incubation
+3 more records
Product overview1 text field

Foresite Labs operates as an AI and data science-focused company incubation platform supporting visionary entrepreneurs building transformative companies across healthcare and life sciences. The platform provides three core capabilities: (1) a team of scientists, engineers, and operators who partner to build companies in AI, science, and technology; (2) integrated AI, data science, and advanced analytics capabilities to extract deeper insights and drive innovation; and (3) a data ecosystem that standardizes and harmonizes data generation and analysis across the portfolio. The platform has incubated notable companies including Prometheus (AI for physical economy, $41B valuation), Xaira Therapeutics (AI-powered drug discovery, $1B Series A), Candid Therapeutics (autoimmune T-cell Engagers, acquired by UCB), and Alumis (TYK2 inhibitors for autoimmune diseases, NASDAQ:ALMS). The company believes AI will greatly accelerate the pace of human discovery and innovation.

Product and service3 records
1Foresite Labs Incubation Platform
CategoryIncubation Platform
Description

An AI- and data-science-driven company formation and incubation platform that supports visionary entrepreneurs building transformative companies. Integrates AI, data science, and advanced analytics with experimental techniques to accelerate scientific discovery and company growth; intended for scientific founders seeking capital, data infrastructure, and operational support.

2Xaira Therapeutics
CategoryIncubated Company — AI Drug Discovery
Description

AI-powered drug discovery company incubated at Foresite Labs, applying AI to learn the language of life and transform how diseases are treated. Released the largest Perturb-Seq dataset in June 2025 to power its Virtual Cell model.

3Alumis
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Foresite Labs

Biotech Incubation Platformforesitelabs.com

Foresite Labs is an AI and data science company incubation platform founded in 2019 that co-builds transformative ventures in life sciences and the physical economy alongside founders, supplying capital, scientific infrastructure, and operational support through a dedicated $173M fund.

What Foresite Labs does

Foresite Labs, LLC is a San Francisco–based AI and data science company incubation platform founded in 2019 by Jim Tananbaum and Vik Bajaj, operating as the operational arm of the broader Foresite organization alongside Foresite Capital (founded 2011, ~$3.5B AUM). The firm identifies scientific and technological opportunities—primarily at the intersection of AI, life sciences, and increasingly the physical economy—and recruits founders to co-build companies, supplying capital, scientific infrastructure, data resources, and operational support through incubation. Its platform integrates AI, data science, and advanced analytics to analyze large-scale clinical, genomic, and multi-omics datasets, with a standardized data ecosystem that compounds learnings across ventures.

Notable incubated companies include Prometheus (AI for the physical economy, co-incubated with Arch Ventures in 2024, $41B valuation by June 2026 with Jeff Bezos as co-CEO), Xaira Therapeutics (AI drug discovery, $1B Series A in April 2024), Alumis (TYK2 inhibitors for autoimmune disease, NASDAQ: ALMS, $345.1M IPO), and Candid Therapeutics (T-cell engagers for autoimmune disease, acquired by UCB in May 2026). Foresite Labs also operates a dedicated $173M fund (launched March 2022) to back portfolio companies, and maintains offices in San Francisco and Boston with a team of approximately 18 scientists, engineers, and operators.

The business model is venture-studio returns: equity creation and appreciation in incubated companies, realized through IPOs, acquisitions, and subsequent financings, supplemented by management fees on the dedicated fund. Foresite Labs does not sell products or services to external customers; rather, it distributes its capabilities through direct partnerships with founders it recruits and co-invests alongside financial partners such as Arch Ventures and Foresite Capital.

Foresite Labs firmographics

Firmographics
Name
Foresite Labs
Legal name
Foresite Labs, LLC
Website
https://foresitelabs.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Foresite Labs is an AI and data science company incubation platform founded in 2019 that co-builds transformative ventures in life sciences and the physical economy alongside founders, supplying capital, scientific infrastructure, and operational support through a dedicated $173M fund.
Ownership category
akta.pro rank

Foresite Labs industry classification

Industry
Product category
Biotech Incubation Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Management Consulting Services (54161)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYFSANAHAC
Corporate Venture Studios & Incubators (Build/launch ventures)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)

Keywords

  • Biotech incubation platform
  • AI drug discovery
  • Venture studio services
  • Company formation platform
  • Data science incubation

Where Foresite Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Foresite Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Portfolio Company Success: Foresite Labs generates returns through successful exits and appreciation of equity stakes in incubated companies. The firm provides incubation services, capital, and operational support to early-stage ventures, with returns realized through IPOs, acquisitions, or subsequent funding rounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Foresite Labs product offering

Product offering

Core offering

Foresite Labs operates an AI- and data-science-driven company incubation platform that identifies scientific opportunities, recruits visionary entrepreneurs, and provides capital, scientific infrastructure, data capabilities, and operational support to co-found and scale transformational companies. Its portfolio spans AI-powered drug discovery (Xaira Therapeutics), autoimmune therapeutics (Alumis, Candid Therapeutics), and AI for the physical economy (Prometheus). The firm monetizes through equity appreciation and successful exits of incubated companies.

Product overview

Foresite Labs operates as an AI and data science-focused company incubation platform supporting visionary entrepreneurs building transformative companies across healthcare and life sciences. The platform provides three core capabilities: (1) a team of scientists, engineers, and operators who partner to build companies in AI, science, and technology; (2) integrated AI, data science, and advanced analytics capabilities to extract deeper insights and drive innovation; and (3) a data ecosystem that standardizes and harmonizes data generation and analysis across the portfolio. The platform has incubated notable companies including Prometheus (AI for physical economy, $41B valuation), Xaira Therapeutics (AI-powered drug discovery, $1B Series A), Candid Therapeutics (autoimmune T-cell Engagers, acquired by UCB), and Alumis (TYK2 inhibitors for autoimmune diseases, NASDAQ:ALMS). The company believes AI will greatly accelerate the pace of human discovery and innovation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Foresite Labs Incubation Platform An AI- and data-science-driven company formation and incubation platform that supports visionary entrepreneurs building transformative companies. Integrates AI, data science, and advanced analytics with experimental techniques to accelerate scientific discovery and company growth; intended for scientific founders seeking capital, data infrastructure, and operational support.
  • Xaira Therapeutics AI-powered drug discovery company incubated at Foresite Labs, applying AI to learn the language of life and transform how diseases are treated. Released the largest Perturb-Seq dataset in June 2025 to power its Virtual Cell model.
  • Alumis

Quantifiable outcome

  • Prometheus reached $41 billion valuation within 2 years of incubation
  • +3 more outcomes

Companies that use Foresite Labs

Customer profile

Segments2 records

Ideal customer profiles2 records

Foresite Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Foresite Labs partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Foresite Labs competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Foresite Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Foresite Labs leadership team

Management profile

Number of profiles

Profiles21 records

Foresite Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Foresite Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foresite Labs

What does Foresite Labs do?

Foresite Labs operates an AI- and data-science-driven company incubation platform that identifies scientific opportunities, recruits visionary entrepreneurs, and provides capital, scientific infrastructure, data capabilities, and operational support to co-found and scale transformational companies. Its portfolio spans AI-powered drug discovery (Xaira Therapeutics), autoimmune therapeutics (Alumis, Candid Therapeutics), and AI for the physical economy (Prometheus). The firm monetizes through equity appreciation and successful exits of incubated companies.

Is Foresite Labs a public or private company?

Foresite Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Foresite Labs founded?

Foresite Labs was founded in 2019. It employs 11 to 50 people.

Where is Foresite Labs based?

Foresite Labs is headquartered in San Francisco, United States, in the North America region.

How does Foresite Labs make money?

One revenue line is on record: portfolio Company Success.

Does Foresite Labs have an API?

No public API is recorded for Foresite Labs.

What industry is Foresite Labs in?

Foresite Labs's product category is Biotech Incubation Platform. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of FSANAAAM, Accelerators & Incubators (Investor-Operated). Its NAICS code is 541714 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizForesite Labs Names Jorge Reis-Filho Chief Strategy Officer and Operating PartnerForesite Labs has appointed Dr. Jorge Reis-Filho as chief strategy officer and operating partner, focusing on building companies that integrate AI, data science, and life sciences. Reis-Filho, who previously worked at AstraZeneca, will also serve as a venture partner at Foresite Capital, contributing to investment strategy across the AI-and-biology markets. This appointment is part of Foresite Labs' ongoing efforts to leverage advances in science and technology to create new biomedical companies.ChinaventureStarting with 1 billion dollars, this year almost all players in this sector have secured funding.Virtual cell companies are securing funding, with Xaira Therapeutics raising $1 billion in 2024. Since April 2026, nearly 10 financing events have occurred, with top investors like Sequoia and Tencent entering. The industry faces data and biology challenges, but AI drug development is entering a new phase.MorningstarForesite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture PartnerForesite Labs appointed Dr. Jorge Reis-Filho as Chief Strategy Officer and Operating Partner, and he will join Foresite Capital as Venture Partner. He previously led AI initiatives at AstraZeneca and will help shape portfolio strategy at the convergence of AI and life sciences.Business Wire BlogForesite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture PartnerForesite Labs appointed Dr. Jorge Reis-Filho as Chief Strategy Officer and Operating Partner, and he will join Foresite Capital as Venture Partner. He previously served as Chief of AI for Science Innovation at AstraZeneca. His appointment follows Foresite Labs' 2024 co-incubations of Xaira, Candid, and Alumis, and co-founding of Prometheus.Investing.comForesite Labs buys Alumis (ALMS) shares worth $7 million By Investing.comForesite Labs, LLC and Foresite Labs Affiliates 2021, LLC purchased a combined 411,764 shares of Alumis Inc. on January 8, 2026, at $17.00 per share, totaling approximately $7 million — below the then-current trading price of $21.09. Alumis has recently completed an upsized public offering raising roughly $345.1 million, with several underwriters including Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities serving as joint book-running managers. Analyst price targets have been raised by Guggenheim (to $32) and Oppenheimer (to $50) following positive Phase III trial results for Alumis's drug Envudeucitinib in psoriasis treatment.YahooXaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugsXaira Therapeutics, an AI drug discovery startup, raised $1 billion from ARCH Venture Partners and Foresite Labs. The company, incubated by the two firms, is ready to start developing drugs using generative AI models from the University of Washington's Institute of Protein Design. Investors expect the technology to be at an inflection point for drug development.YahooXaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugsXaira Therapeutics, an AI drug discovery startup, raised $1 billion from ARCH Venture Partners and Foresite Labs, with other investors including Sequoia and NEA. CEO Marc Tessier-Lavigne said the company is ready to develop drugs impossible to make without recent AI breakthroughs. The company declined to say when it expects its first drug for human trials.YahooXaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugsXaira Therapeutics, an AI drug discovery startup, raised $1 billion from ARCH Venture Partners and Foresite Labs, with other investors including Sequoia and NEA. CEO Marc Tessier-Lavigne, a former Stanford president, said the company is ready to develop drugs, though no timeline for first human trials was given.pharmaphorumEnter Xaira, with $1bn for its AI in drug discovery platformXaira Therapeutics, a San Francisco-based AI drug discovery startup, raised over $1 billion in funding from ARCH Venture Partners, Foresite Labs, and other investors. The company, led by Marc Tessier-Lavigne, will use its AI platform to design proteins and antibodies for drug development.